A Reappraisal of Thymosin Alpha1 in Cancer Therapy
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing preclinical and clinical literature with mechanism-based reasoning.
OpenAlex W2969768554 · doi:10.3389/fonc.2019.00873
What was done
This narrative review summarizes the historical development, mechanisms of action, and clinical evidence for thymosin alpha1 (Tα1) as an adjuvant immunomodulator in cancer therapy, with particular focus on melanoma, hepatocellular carcinoma, and lung cancer, as well as its rationale for use in combination with immune checkpoint inhibitors.
What was found
The abstract reports no numerical data, effect estimates, or statistical outcomes. It qualitatively describes preclinical and clinical findings indicating immunostimulatory activity and potential benefits of Tα1 when integrated into combination chemotherapy and immunotherapy protocols.
Why it matters
It highlights the mechanistic basis for combining thymosin alpha1 with modern immune checkpoint inhibitors to potentially improve therapeutic response rates and manage shortcomings in efficacy and safety.
Limits
The paper is a narrative overview rather than a systematic review or primary trial, lacking structured search methods, risk-of-bias evaluation, and pooled quantitative data. No specific patient counts or outcome measurements are provided in the abstract.
Cited by
- supports Allan Goldstein's laboratory isolated thymosin fraction 5 and identified thymosin alpha-1 and thymosin beta-4 from thymic tissue.